Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cancer & Antibody Conjugates Patent Landscape Report: Evaluating 3,761 Patent Families, Linker-Payload Technologies, and Strategies of Roche, Daiichi Sankyo, Gilead, and AstraZeneca

globenewswire.com
GILD Gilead is listed among established pharmaceutical companies that are expanding their patent portfolios in the cancer antibody conjugates field. The article notes its participation but doesn't provide specific sentiment on its performance. AZN AstraZeneca is mentioned as an established pharmaceutical company with a significant presence in the cancer antibody conjugates patent landscape. The article highlights its role but does not offer specific positive or negative sentiment. PFE Pfizer is listed as an established pharmaceutical company involved in patent filings for cancer antibody conjugates. The article acknowledges its participation in the field but does not offer specific sentiment. BMY Bristol Myers Squibb is identified as an established pharmaceutical company contributing to patent activity in the cancer antibody conjugates space. The article notes its presence but provides no specific sentiment. ABBV AbbVie is mentioned as an established pharmaceutical company with patent activity in the cancer antibody conjugates field. The article acknowledges its involvement but does not provide specific sentiment.

Cancer & Antibody Conjugates Patent Landscape Report: Evaluating 3,761 Patent Families, Linker-Payload Technologies, and Strategies of Roche, Daiichi Sankyo, Gilead, and AstraZeneca Dublin, Aug. 17, 2026 (GLOBE NEWSWIRE) -- The "Cancer & Antibody Conjugates Patent Landscape Analysis 2025" has been added to ResearchAndMarkets.com's offering.

Cancer Antibody Conjugates Patent Landscape Report Delivers Strategic Insights into ADCs and Radioimmunoconjugates

A comprehensive cancer antibody conjugates patent landscape report provides actionable intelligence on antibody-drug conjugates (ADCs), radioimmunoconjugates and the intellectual property strategies shaping the future of targeted oncology. Combining a PDF report of more than 100 slides with an Excel database covering 3,761 patent families, the study enables pharmaceutical companies, biotechnology firms, investors and research organizations to evaluate competition, identify innovation trends and support strategic decision-making.

Cancer antibody conjugates continue to transform oncology by integrating monoclonal antibodies with cytotoxic drugs or radionuclides. Approximately 15 ADCs have received approval worldwide for hematologic malignancies and solid tumors, while more than 200 additional candidates are advancing through clinical trials and over 400 are reported to be in development. Radioimmunoconjugates are also attracting renewed interest as advances in immuno-oncology, radionuclide technologies and combination treatment strategies create new therapeutic opportunities.

Despite strong clinical and commercial momentum, the sector faces significant challenges involving toxicity, treatment resistance, manufacturing complexity, conjugate stability and radioisotope handling. Against this backdrop, a detailed understanding of patent activity related to antibodies, targets, payloads, linkers, radionuclides and conjugation technologies is essential for assessing freedom to operate, anticipating competitive threats and identifying licensing or partnership opportunities.

Key Report Features

Patent Filing Activity Reflects Rapid ADC Market Expansion

The patent landscape shows a prolonged exploratory period from the late 1970s through the mid-2000s, when annual filings remained limited and were largely driven by early pharmaceutical innovators and academic cancer centers. Patent activity accelerated as ADCs achieved clinical validation and gained traction in hematologic malignancies and breast cancer.

Following 2010, annual patent filings increased sharply alongside the clinical development and approval of next-generation ADC products. Between 2018 and 2024, yearly filings more than doubled, approaching 500 new patent families annually. This growth was supported by investment in potent topoisomerase I inhibitor payloads, including deruxtecan- and govitecan-related technologies, as well as advances in cleavable linkers, site-specific conjugation and solid tumor applications.

The competitive environment has also expanded beyond established pharmaceutical companies such as Roche/Genentech, Novartis, Pfizer, Bristol Myers Squibb, AbbVie, AstraZeneca and Gilead. Specialized biotechnology companies and rapidly growing Asian innovators, including Daiichi Sankyo and Hengrui, now contribute substantially to worldwide patent activity. Recent filing patterns indicate increasing portfolio consolidation and broader geographic protection within a market that remains highly innovative.

Detailed Technology Segmentation

The report organizes the cancer antibody conjugates patent landscape around three principal technology areas: antibodies, linkers and payloads. Eight segmentation categories are included. Antibody-related patents are classified by liquid cancer, liquid cancer only, solid cancer and solid cancer only, based on patent claims. Linker technologies are divided into cleavable and uncleavable categories, while payloads are segmented into drugs and radioisotopes.

This structure supports targeted analysis of research priorities, technology maturity, portfolio overlap and competitive positioning. Users can compare patent ownership across individual technology segments and identify areas with high filing intensity or potential opportunities for differentiation.

New Entrants and Competitive Opportunities

The study identifies 147 intellectual property newcomers in the cancer antibody conjugates landscape. These organizations include start-ups and established companies filing their first patents in the field. China accounts for 76 of the identified newcomers, highlighting the country's growing role in ADC research, manufacturing and commercialization. Monitoring these emerging companies can help established market participants identify potential acquisition targets, licensing partners and future competitors.

Profiles of Leading Patent Owners

Profiles of major patent assignees include company background, portfolio composition, patent publication trends, geographic coverage and active patents by technical segment. The report also examines the technological content of strategically important patents and provides relevant clinical trial information, supporting a clearer assessment of each company's innovation strategy and market position.

The accompanying Excel database enables multi-criteria searches across all 3,761 patent families. Available data include publication numbers, priority dates, titles, abstracts, assignees, legal status, technology segmentation and hyperlinks to original patent documents. Access to the online patent database further supports ongoing monitoring through updated legal status information for individual patent records.

Key Topics Covered:

INTRODUCTION

EXECUTIVE SUMMARY

PATENT LANDSCAPE OVERVIEW

NEWCOMERS

IP POSITION OF MAIN APPLICANTS

PATENT SEGMENTATION

IP PROFILE OF KEY PLAYERS

METHODOLOGY

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/8k6l7w

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.